Highlights
• Several food-derived peptides have been shown to inhibit the HMG-CoAR activity.
• Biopeptides inhibit HMG-CoAR activity by competitive or non-competitive mechanisms.
• Physicochemical characteristics of peptides define the type of enzyme inhibition.
• Food-derived peptides may help to reduce the side effects of statin therapy.
• Biopeptides are potential compounds as future hypocholesterolemic treatments.
Graphical Abstract
View original image
Download original image
Abstract
Cardiovascular diseases (CVDs) are the leading global cause of mortality and disease burden. Statins are the most prescribed lipid-lowering drugs to treat hypercholesterolemia and prevent CVDs. The biochemical mechanism of statins consists of competitive inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme (HMG-CoAR), the limiting enzyme in cholesterol biosynthesis. Due to statin intolerance in some patient groups, the search for new inhibitors is a field of great interest. This review focusses on the studies reporting the inhibitory effect of protein hydrolysates and biopeptides on the HMG-CoAR enzyme activity. The analysis of the action mechanism and physicochemical characteristics of the HMG-CoAR inhibitory peptides revealed that the molecular weight, amino acid composition, charge, and polarity are key aspects of the interaction with the HMG-CoAR enzyme. In conclusion, this review reveals the potential of using food peptides as new cholesterol-lowering agents and opens a new interesting field of research. However, clinical approaches are mandatory to confirm their therapeutic hypercholesterolemic effect.